Vernal keratoconjunctivitis (VKC) is a chronic, recurrent, bilateral inflammatory disease showing exacerbations during the spring and summer seasons, affecting young children. Present study was conducted with the aim of comparing the efficacy of cyclosporine 0.05% with olopatadine 0.1% in recalcitrant patients of VKC.
Materials and methods
A prospective randomized controlled trial was performed on 40 eyes (20 patients of recalcitrant VKC) during the period of May 2015 to September 2015. A short course of mild steroid was given for 5 days to all patients as they presented with acute exacerbation of recalcitrant VKC.
Left eye of each patient received topical cyclosporine 0.05%, which is a nonsteroidal immunomodulator, twice daily, and right eye of the same patient received olopatadine 0.1%, which has a dual action, i.e., mast cell stabilizer action as well as antihistaminic activity, twice daily for a period of 3 months. Grading of signs and symptoms was done at the time of presentation and at 2 weeks, 1 month, and 3 months interval.
When compared with baseline, scores for signs and symptoms at 2 weeks reduced significantly for both cyclosporine and olopatadine. However, at 3 months, scores as regards signs and symptoms were found to be lower in cyclosporine as compared with olopatadine eyes.
Cyclosporine 0.05% was found to be equally effective in treating signs and symptoms as olopatadine in the early phase of the treatment. But, a significant improvement was noted in cyclosporine eyes as compared with olopatadine eyes in the late period.
How to cite this article
Goyal E, Devendra J, Gupta P. Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis. Int J Adv Integ Med Sci 2016;1(4):139-142.